DNA High-Tech Background

Explore Cancer Types

Empowerment Through Tissue Preservation

Every cancer operates uniquely, demanding highly specific clinical interventions. Select a cancer type below to learn more about its biology and specifically why retaining ownership of your living tumor tissue grants unprecedented access to personalized diagnostics and emerging clinical trials.

Sarcoma

Over 70 sub-types of bone and soft tissue cancers. Ex-vivo testing maps their unique structural resistances.

Pancreatic Cancer

A notoriously hidden, hyper-aggressive disease demanding rapid molecular insights right from biopsy.

Stomach Cancer

Complex gastric tumors that heavily compromise digestion, mandating tailored precision interventions.

Ovarian Cancer

Often presenting asymptomatically at first, with a complex tendency of cellular recurrence post-surgery.

Esophageal Cancer

Developing in digestive swallowing pathways necessitating intensive multimodal therapies mapped to unique biology.

Colorectal Cancer

Lower digestive tumors with incredibly varied resistance mechanisms perfect for functional drug matching.

Glioblastoma

Hyper-aggressive brain tumors requiring personalized dendritic vaccines crafted intimately from their living tissue.

Cholangiocarcinoma

Rare bile duct cancers with immense genomic alteration incidence capable of unlocking massive targeted trial inclusion.

Mesothelioma

Asbestos-related lung encasement tumors highly susceptible to groundbreaking clinical immunomodulatory screening.

Neuroendocrine Tumors (NETs)

Rare networks of hormone-secreting tumors where identifying living cell receptors proves vital for precision radiation routing.

Appendiceal Cancer

Appendix-based malignancies driving complex abdominal surgeries requiring off-body chemo-sensitivity testing.

Liver Cancer

Hepatocellular carcinomas with highly complex microenvironments demanding rigorous ex-vivo molecular profiling.

Lung Cancer

Highly mutated respiratory tumors where abundant tissue ensures failure-proof biomarker discovery and immune mapping.

Breast Cancer

Complex ductal and lobular carcinomas where subtyping and 3D organoid testing unlock precision regimens.

Prostate Cancer

Androgen-driven malignancies where tissue modeling combats treatment resistance and unlocks radioligand trials.

Kidney Cancer

Chemo-resistant renal cell carcinomas demanding precise immunological and anti-angiogenic testing.

Bladder Cancer

Highly recurrent urothelial tumors where living tissue mapping dictates the use of novel Antibody-Drug Conjugates.

Melanoma

Super-aggressive metastatic melanomas that serve as the frontier for personalized immune and TIL cellular therapies.